Skip to main content
. 2021 Aug 16;11:16541. doi: 10.1038/s41598-021-95970-z

Table 1.

Characteristics of analysis population.

All (n = 4516)
Age (years)* [nmiss = 0] 59.6 ± 7.8
Female Sex# 2256 (50.0%)
Serum lipid concentration (mg/dl)*
HDL-C [nmiss = 1] 58.16 ± 17.29
LDL-C [nmiss = 14] 145.41 ± 36.21
TC [nmiss = 0] 229.26 ± 39.18
Lipid-lowering medication [nmiss = 289]# 557 (13.2%)
Number of lipid effect alleles (GESLipid§)*
GESHDL-C [nmiss = 0] 78.3 ± 5.1
GESLDL-C [nmiss = 0] 55.1 ± 4.5
GESTC [nmiss = 0] 75.7 ± 5.2
Number of lipid effect alleles (GESLipid-EXT+)*
GESHDL-C-EXT [nmiss = 0] 136.4 ± 6.6
GESLDL-C-EXT [nmiss = 0] 93.6 ± 5.9
GESTC-EXT [nmiss = 0] 126.2 ± 6.6
Education (years of training)# [nmiss = 13]
 ≤ 10 515 (11.4%)
11–13 2502 (55.6%)
 ≥ 14 1486 (33.0%)
Income (€/month) † [nmiss = 283] 1448.7 (1107.8–1874.7)
Body mass index (kg/m2)* [nmiss = 25] 27.92 ± 4.64
No physical activity# 2302 (51.0%)
Current smoking# [nmiss = 7] 1069 (23.7%)
Alcohol consumption† (g/week) [nmiss = 112] 13.9 (0–64.5)
Diabetes mellitus # 615 (13.6%)

nmiss = number of participants with missing values, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TC = total cholesterol, GES = genetic effect allele sum score, diabetes mellitus is defined as self-reported diabetes mellitus, or fasting blood glucose level ≥ 126 mg/dl or postprandial blood glucose level ≥ 200 mg/dl or if the use of anti-diabetic medication was documented.

*Mean ± standard deviation (SD)

#Proportion (%)

Median (first quartile-third quartile)

§GESLipid based on14

+GESLipid-EXT based on1417